Corient Private Wealth
RXRX icon

Corient Private Wealth’s Recursion Pharmaceuticals RXRX Stock Holding History

Corient Private Wealth’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$189K Buy
+51,561
New +$172K ﹤0.01% 2824
2026
Q1 		– Sell
-17,096
Closed -$69.9K – 2967
2025
Q4 		$69.9K Buy
+17,096
New +$84.7K ﹤0.01% 2579

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Corient Private Wealth's RXRX Position: Q2 2026 in Review

Corient Private Wealth opened a new position in Recursion Pharmaceuticals (RXRX) in Q2 2026: 51,561 shares worth $189K. The stake represents ﹤0.01% of the portfolio and ranks #2824 among its holdings. This is a return to the name: Corient Private Wealth previously reported a position in RXRX as recently as Q4 2025.

Corient Private Wealth first reported a position in RXRX in Q4 2025 and has held it in 2 quarters since. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Corient Private Wealth held 51,561 shares of Recursion Pharmaceuticals worth $189K as of Q2 2026.
  • Recursion Pharmaceuticals was a new Corient Private Wealth position in Q2 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #2824 holding.
  • Corient Private Wealth first reported a position in Recursion Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.